Evidence map›Paper›PMID 36753752›Full record

ArticleBioconjugate chemistry2023

Resorc[4]arene-Modified Gold-Decorated Magnetic Nanoparticles for Immunosensor Development.

Andrea Calcaterra, Francesca Polli, Lara Lamelza, Cristina Del Plato, Silvia Cammarone, Francesca Ghirga, Bruno Botta, Franco Mazzei, Deborah Quaglio

Open access · hybridFull text read
In one paragraph

Article in Bioconjugate chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Andrea CalcaterraDepartment of Chemistry and Technology of Drugs, Department of Excellence 2018-2022, Sapienza─University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0001-7036-6620
Francesca PolliDepartment of Chemistry and Technology of Drugs, Department of Excellence 2018-2022, Sapienza─University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.
Lara LamelzaDepartment of Chemistry and Technology of Drugs, Department of Excellence 2018-2022, Sapienza─University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.
Cristina Del PlatoDepartment of Chemistry and Technology of Drugs, Department of Excellence 2018-2022, Sapienza─University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.
Silvia CammaroneDepartment of Chemistry and Technology of Drugs, Department of Excellence 2018-2022, Sapienza─University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.
Francesca GhirgaDepartment of Chemistry and Technology of Drugs, Department of Excellence 2018-2022, Sapienza─University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0002-5591-5190
Bruno BottaDepartment of Chemistry and Technology of Drugs, Department of Excellence 2018-2022, Sapienza─University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0001-8707-4333
Franco MazzeiDepartment of Chemistry and Technology of Drugs, Department of Excellence 2018-2022, Sapienza─University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.
Deborah QuaglioDepartment of Chemistry and Technology of Drugs, Department of Excellence 2018-2022, Sapienza─University of Rome, P.le Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0001-7762-8283
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent years, several efforts have been made to develop selective, sensitive, fast response, and miniaturized immunosensors with improved performance for the monitoring and screening of analytes in several matrices, significantly expanding the use of this technology in a broad range of applications. However, one of the main technical challenges in developing immunosensors is overcoming the complexity of binding antibodies (Abs) to the sensor surface. Most immobilizing approaches lead to a random orientation of Abs, resulting in lower binding site density and immunoaffinity. In this context, supramolecular chemistry has emerged as a suitable surface modification tool to achieve the preorganization of artificial receptors and to improve the functional properties of self-assembled monolayers. Herein, a supramolecular chemistry/nanotechnology-based platform was conceived to develop sensitive label-free electrochemical immunosensors, by using a resorcarene macrocycle as an artificial linker for the oriented antibody immobilization. To this aim, a water-soluble bifunctional resorc[4]arene architecture (RW) was rationally designed and synthesized to anchor gold-coated magnetic nanoparticles (Au@MNPs) and to maximize the amount of the active immobilized antibody (Ab) in the proper "end-on" orientation. The resulting supramolecular chemistry-modified nanoparticles, RW@Au@MNPs, were deposited onto graphite screen printed electrodes which were then employed to immobilize three different Abs. Furthermore, an immunosensor for atrazine (ATZ) analysis was realized and characterized by the differential pulse voltammetry technique to demonstrate the validity of the developed biosensing platform as a proof of concept for electrochemical immunosensors. The RW-based immunosensor improved Ab

Indexed as

Biosensing TechniquesMagnetite NanoparticlesMetal NanoparticlesAntibodiesElectrochemical TechniquesElectrodesGoldImmunoassayLimit of DetectionReproducibility of ResultsAntibodiesGoldMagnetite Nanoparticles

Identifiers

PMID36753752
PMCPMC10020960
OpenAlexW4319458012

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read48
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.